Copyright Reports & Markets. All rights reserved.

Global Circulating Tumor DNA Diagnostics Market Growth (Status and Outlook) 2022-2028

Request for Sample of this report
Buy now

1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Circulating Tumor DNA Diagnostics Market Size 2017-2028
    • 2.1.2 Circulating Tumor DNA Diagnostics Market Size CAGR by Region 2017 VS 2022 VS 2028
  • 2.2 Circulating Tumor DNA Diagnostics Segment by Type
    • 2.2.1 Test Kits
    • 2.2.2 Reagents
  • 2.3 Circulating Tumor DNA Diagnostics Market Size by Type
    • 2.3.1 Circulating Tumor DNA Diagnostics Market Size CAGR by Type (2017 VS 2022 VS 2028)
    • 2.3.2 Global Circulating Tumor DNA Diagnostics Market Size Market Share by Type (2017-2022)
  • 2.4 Circulating Tumor DNA Diagnostics Segment by Application
    • 2.4.1 Hospitals
    • 2.4.2 Diagnostics Laboratories
    • 2.4.3 Research Laboratories
    • 2.4.4 Academic Research Institutes
  • 2.5 Circulating Tumor DNA Diagnostics Market Size by Application
    • 2.5.1 Circulating Tumor DNA Diagnostics Market Size CAGR by Application (2017 VS 2022 VS 2028)
    • 2.5.2 Global Circulating Tumor DNA Diagnostics Market Size Market Share by Application (2017-2022)

3 Circulating Tumor DNA Diagnostics Market Size by Player

  • 3.1 Circulating Tumor DNA Diagnostics Market Size Market Share by Players
    • 3.1.1 Global Circulating Tumor DNA Diagnostics Revenue by Players (2020-2022)
    • 3.1.2 Global Circulating Tumor DNA Diagnostics Revenue Market Share by Players (2020-2022)
  • 3.2 Global Circulating Tumor DNA Diagnostics Key Players Head office and Products Offered
  • 3.3 Market Concentration Rate Analysis
    • 3.3.1 Competition Landscape Analysis
    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
  • 3.4 New Products and Potential Entrants
  • 3.5 Mergers & Acquisitions, Expansion

4 Circulating Tumor DNA Diagnostics by Regions

  • 4.1 Circulating Tumor DNA Diagnostics Market Size by Regions (2017-2022)
  • 4.2 Americas Circulating Tumor DNA Diagnostics Market Size Growth (2017-2022)
  • 4.3 APAC Circulating Tumor DNA Diagnostics Market Size Growth (2017-2022)
  • 4.4 Europe Circulating Tumor DNA Diagnostics Market Size Growth (2017-2022)
  • 4.5 Middle East & Africa Circulating Tumor DNA Diagnostics Market Size Growth (2017-2022)

5 Americas

  • 5.1 Americas Circulating Tumor DNA Diagnostics Market Size by Country (2017-2022)
  • 5.2 Americas Circulating Tumor DNA Diagnostics Market Size by Type (2017-2022)
  • 5.3 Americas Circulating Tumor DNA Diagnostics Market Size by Application (2017-2022)
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Circulating Tumor DNA Diagnostics Market Size by Region (2017-2022)
  • 6.2 APAC Circulating Tumor DNA Diagnostics Market Size by Type (2017-2022)
  • 6.3 APAC Circulating Tumor DNA Diagnostics Market Size by Application (2017-2022)
  • 6.4 China
  • 6.5 Japan
  • 6.6 Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia

7 Europe

  • 7.1 Europe Circulating Tumor DNA Diagnostics by Country (2017-2022)
  • 7.2 Europe Circulating Tumor DNA Diagnostics Market Size by Type (2017-2022)
  • 7.3 Europe Circulating Tumor DNA Diagnostics Market Size by Application (2017-2022)
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Circulating Tumor DNA Diagnostics by Region (2017-2022)
  • 8.2 Middle East & Africa Circulating Tumor DNA Diagnostics Market Size by Type (2017-2022)
  • 8.3 Middle East & Africa Circulating Tumor DNA Diagnostics Market Size by Application (2017-2022)
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Global Circulating Tumor DNA Diagnostics Market Forecast

  • 10.1 Global Circulating Tumor DNA Diagnostics Forecast by Regions (2023-2028)
    • 10.1.1 Global Circulating Tumor DNA Diagnostics Forecast by Regions (2023-2028)
    • 10.1.2 Americas Circulating Tumor DNA Diagnostics Forecast
    • 10.1.3 APAC Circulating Tumor DNA Diagnostics Forecast
    • 10.1.4 Europe Circulating Tumor DNA Diagnostics Forecast
    • 10.1.5 Middle East & Africa Circulating Tumor DNA Diagnostics Forecast
  • 10.2 Americas Circulating Tumor DNA Diagnostics Forecast by Country (2023-2028)
    • 10.2.1 United States Circulating Tumor DNA Diagnostics Market Forecast
    • 10.2.2 Canada Circulating Tumor DNA Diagnostics Market Forecast
    • 10.2.3 Mexico Circulating Tumor DNA Diagnostics Market Forecast
    • 10.2.4 Brazil Circulating Tumor DNA Diagnostics Market Forecast
  • 10.3 APAC Circulating Tumor DNA Diagnostics Forecast by Region (2023-2028)
    • 10.3.1 China Circulating Tumor DNA Diagnostics Market Forecast
    • 10.3.2 Japan Circulating Tumor DNA Diagnostics Market Forecast
    • 10.3.3 Korea Circulating Tumor DNA Diagnostics Market Forecast
    • 10.3.4 Southeast Asia Circulating Tumor DNA Diagnostics Market Forecast
    • 10.3.5 India Circulating Tumor DNA Diagnostics Market Forecast
    • 10.3.6 Australia Circulating Tumor DNA Diagnostics Market Forecast
  • 10.4 Europe Circulating Tumor DNA Diagnostics Forecast by Country (2023-2028)
    • 10.4.1 Germany Circulating Tumor DNA Diagnostics Market Forecast
    • 10.4.2 France Circulating Tumor DNA Diagnostics Market Forecast
    • 10.4.3 UK Circulating Tumor DNA Diagnostics Market Forecast
    • 10.4.4 Italy Circulating Tumor DNA Diagnostics Market Forecast
    • 10.4.5 Russia Circulating Tumor DNA Diagnostics Market Forecast
  • 10.5 Middle East & Africa Circulating Tumor DNA Diagnostics Forecast by Region (2023-2028)
    • 10.5.1 Egypt Circulating Tumor DNA Diagnostics Market Forecast
    • 10.5.2 South Africa Circulating Tumor DNA Diagnostics Market Forecast
    • 10.5.3 Israel Circulating Tumor DNA Diagnostics Market Forecast
    • 10.5.4 Turkey Circulating Tumor DNA Diagnostics Market Forecast
    • 10.5.5 GCC Countries Circulating Tumor DNA Diagnostics Market Forecast
  • 10.6 Global Circulating Tumor DNA Diagnostics Forecast by Type (2023-2028)
  • 10.7 Global Circulating Tumor DNA Diagnostics Forecast by Application (2023-2028)

11 Key Players Analysis

  • 11.1 Grail, Inc.
    • 11.1.1 Grail, Inc. Company Information
    • 11.1.2 Grail, Inc. Circulating Tumor DNA Diagnostics Product Offered
    • 11.1.3 Grail, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2020-2022)
    • 11.1.4 Grail, Inc. Main Business Overview
    • 11.1.5 Grail, Inc. Latest Developments
  • 11.2 Guardant Health, Inc.
    • 11.2.1 Guardant Health, Inc. Company Information
    • 11.2.2 Guardant Health, Inc. Circulating Tumor DNA Diagnostics Product Offered
    • 11.2.3 Guardant Health, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2020-2022)
    • 11.2.4 Guardant Health, Inc. Main Business Overview
    • 11.2.5 Guardant Health, Inc. Latest Developments
  • 11.3 Biodesix, Inc.
    • 11.3.1 Biodesix, Inc. Company Information
    • 11.3.2 Biodesix, Inc. Circulating Tumor DNA Diagnostics Product Offered
    • 11.3.3 Biodesix, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2020-2022)
    • 11.3.4 Biodesix, Inc. Main Business Overview
    • 11.3.5 Biodesix, Inc. Latest Developments
  • 11.4 Exosome Diagnostics
    • 11.4.1 Exosome Diagnostics Company Information
    • 11.4.2 Exosome Diagnostics Circulating Tumor DNA Diagnostics Product Offered
    • 11.4.3 Exosome Diagnostics Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2020-2022)
    • 11.4.4 Exosome Diagnostics Main Business Overview
    • 11.4.5 Exosome Diagnostics Latest Developments
  • 11.5 Freenome Inc.
    • 11.5.1 Freenome Inc. Company Information
    • 11.5.2 Freenome Inc. Circulating Tumor DNA Diagnostics Product Offered
    • 11.5.3 Freenome Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2020-2022)
    • 11.5.4 Freenome Inc. Main Business Overview
    • 11.5.5 Freenome Inc. Latest Developments
  • 11.6 LungLife AI, Inc.
    • 11.6.1 LungLife AI, Inc. Company Information
    • 11.6.2 LungLife AI, Inc. Circulating Tumor DNA Diagnostics Product Offered
    • 11.6.3 LungLife AI, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2020-2022)
    • 11.6.4 LungLife AI, Inc. Main Business Overview
    • 11.6.5 LungLife AI, Inc. Latest Developments
  • 11.7 Inivata Ltd.
    • 11.7.1 Inivata Ltd. Company Information
    • 11.7.2 Inivata Ltd. Circulating Tumor DNA Diagnostics Product Offered
    • 11.7.3 Inivata Ltd. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2020-2022)
    • 11.7.4 Inivata Ltd. Main Business Overview
    • 11.7.5 Inivata Ltd. Latest Developments
  • 11.8 Personal Genome Diagnostics, Inc.
    • 11.8.1 Personal Genome Diagnostics, Inc. Company Information
    • 11.8.2 Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Product Offered
    • 11.8.3 Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2020-2022)
    • 11.8.4 Personal Genome Diagnostics, Inc. Main Business Overview
    • 11.8.5 Personal Genome Diagnostics, Inc. Latest Developments
  • 11.9 CellMax Life
    • 11.9.1 CellMax Life Company Information
    • 11.9.2 CellMax Life Circulating Tumor DNA Diagnostics Product Offered
    • 11.9.3 CellMax Life Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2020-2022)
    • 11.9.4 CellMax Life Main Business Overview
    • 11.9.5 CellMax Life Latest Developments

12 Research Findings and Conclusion

The global market for Circulating Tumor DNA Diagnostics is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC Circulating Tumor DNA Diagnostics market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States Circulating Tumor DNA Diagnostics market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe Circulating Tumor DNA Diagnostics market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China Circulating Tumor DNA Diagnostics market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key Circulating Tumor DNA Diagnostics players cover Grail, Inc., Guardant Health, Inc., Biodesix, Inc., Exosome Diagnostics and Freenome Inc., etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage
This latest report provides a deep insight into the global Circulating Tumor DNA Diagnostics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global Circulating Tumor DNA Diagnostics market, with both quantitative and qualitative data, to help readers understand how the Circulating Tumor DNA Diagnostics market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.

Market Segmentation:
The study segments the Circulating Tumor DNA Diagnostics market and forecasts the market size by Type (Test Kits and Reagents,), by Application (Hospitals, Diagnostics Laboratories, Research Laboratories and Academic Research Institutes), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type
Test Kits
Reagents

Segmentation by application
Hospitals
Diagnostics Laboratories
Research Laboratories
Academic Research Institutes

Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Major companies covered
Grail, Inc.
Guardant Health, Inc.
Biodesix, Inc.
Exosome Diagnostics
Freenome Inc.
LungLife AI, Inc.
Inivata Ltd.
Personal Genome Diagnostics, Inc.
CellMax Life

Chapter Introduction
Chapter 1: Scope of Circulating Tumor DNA Diagnostics, Research Methodology, etc.
Chapter 2: Executive Summary, global Circulating Tumor DNA Diagnostics market size and CAGR, Circulating Tumor DNA Diagnostics market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Circulating Tumor DNA Diagnostics revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Circulating Tumor DNA Diagnostics revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Circulating Tumor DNA Diagnostics market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Grail, Inc., Guardant Health, Inc., Biodesix, Inc., Exosome Diagnostics, Freenome Inc., LungLife AI, Inc., Inivata Ltd., Personal Genome Diagnostics, Inc. and CellMax Life. etc.
Chapter 14: Research Findings and Conclusion

Buy now